Sen. Charles Grassley, one of the lawmakers who questioned Mylan NV over the EpiPen price increases, said he isn't satisfied with the Southpointe pharmaceutical's response released Friday.
Mylan (Nasdaq: MYL) sent a seven-page letter to Grassley, saying that about 85 percent of people who get the EpiPen don't pay the full price and that Mylan is working to help the others who do, including rolling out a generic version of the two-pack pens to counteract serious and life-threatening allergy attacks.…
Sen. Charles Grassley, one of the lawmakers who questioned Mylan NV over the EpiPen price increases, said he isn't satisfied with the Southpointe pharmaceutical's response released Friday.
Mylan (Nasdaq: MYL) sent a seven-page letter to Grassley, saying that about 85 percent of people who get the EpiPen don't pay the full price and that Mylan is working to help the others who do, including rolling out a generic version of the two-pack pens to counteract serious and life-threatening allergy attacks.…